Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

77.86
Delayed Data
As of Sep 29
 -1.11 / -1.41%
Today’s Change
76.67
Today|||52-Week Range
111.11
-23.06%
Year-to-Date
Gilead Sciences Stock Downgraded: 3 Things You Need to Know
Sep 28 / MotleyFool.com - Paid Partner Content
Analysts' Actions -- AutoZone, Eli Lilly, J.M. Smucker, Toll Brothers and More
Sep 27 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Amgen's Kyprolis Disappoints, Array Up on Cancer Data
Sep 28 / Zacks.com - Paid Partner Content
5 Safe Stocks to Buy Today
Sep 27 / MotleyFool.com - Paid Partner Content
Why Cash Is King for Biotech Stocks
Sep 27 / MotleyFool.com - Paid Partner Content
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Jim Cramer -- Gilead Needs to Make an Acquisition
Sep 27 / TheStreet.com - Paid Partner Content
This Hated Pharma Stock Has A Bright Future
Sep 26 / StreetAuthority - Paid Partner Content
Gilead (GILD) Stock Falls on Ratings Downgrade
Sep 27 / TheStreet.com - Paid Partner Content
Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Become...
Sep 26 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close78.97
Today’s open79.16
Day’s range77.75 - 79.34
Volume7,618,560
Average volume (3 months)10,093,427
Market cap$104.2B
Dividend yield2.41%
Data as of 4:14pm ET, 09/29/2016

Growth & Valuation

Earnings growth (last year)+62.04%
Earnings growth (this year)-6.75%
Earnings growth (next 5 years)+1.00%
Revenue growth (last year)+28.71%
P/E ratio6.9
Price/Sales4.80
Price/Book6.06

Competitors

 Today’s
change
Today’s
% change
AMGNAmgen-4.26-2.51%
BIIBBiogen-4.77-1.54%
ILMNIllumina Inc-4.42-2.44%
NBIXNeurocrine Bioscienc...-1.09-2.12%
Data as of 3:59pm ET, 09/29/2016

Financials

Next reporting dateOctober 25, 2016
EPS forecast (this quarter)$2.88
Annual revenue (last year)$32.0B
Annual profit (last year)$18.1B
Net profit margin56.52%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John F. Milligan
Chief Operating Officer
Kevin B. Young
Corporate headquarters
Foster City, California

Forecasts

Search for Jobs